Tiny Biotech Stock Triples After FDA Authorizes Dermatitis Study

(Bloomberg) -- Edesa Biotech Inc. shares tripled after the U.S. Food and Drug Administration said the company could proceed with its clinical study of a potential new treatment for dermatitis.

Bloomberg Quint

Add BloombergQuint App to Home screen.